Image source: Getty Images
On both sides of the Atlantic, there have been plenty of warnings of a stock market correction or, worse, a full-blown crash. Concerns that we’re in the middle of an artificial intelligence bubble are driving these fears.
But despite these worrying predictions, I’m continuing to buy UK shares. Here are a couple that I recently bought.
Cheers!
Not to be confused with the US company, Coca-Cola HBC (LSE:CCH) holds the exclusive rights to distribute the American group’s drinks in 28 countries in Europe and Africa.
Analysts are expecting strong earnings growth over the next five years with emerging markets being the biggest contributor. If these forecasts prove accurate, based on a current (19 January) share price of £39.16 (€45.16), it implies a forward (2029) price-to-earnings ratio of 11.8. This would be incredibly cheap for the sector, the FTSE 100, and — based on history — for the stock itself.
| Year | Forecast earnings per share (€) | Change (%) | Forward price-to-earnings ratio |
|---|---|---|---|
| 2024 | 2.28 (actual) | +9.5 | 19.8 |
| 2025 | 2.63 | +15.4 | 17.2 |
| 2026 | 2.86 | +8.8 | 15.8 |
| 2027 | 3.14 | +9.8 | 14.4 |
| 2028 | 3.48 | +10.8 | 13.0 |
| 2029 | 3.82 | +9.8 | 11.8 |
A 69% increase in its dividend is also predicted, lifting the stock’s yield to 3.9%.
These forecasts were compiled before the group announced its intention to acquire 75% of Coca-Cola Beverages Africa for $2.6bn. This will give the group access to another 14 countries accounting for approximately 40% of sales volumes on the continent.
Although it remains a highly competitive industry and there are fears that weight-loss drugs could affect demand, I like the group’s policy of having a drink for every occasion round the clock. And it’s more than about Coca-Cola. Set alongside these impressive forecasts, that’s why I decided to add the stock to my portfolio and why others could consider doing the same.
A big reboot
After suffering a torrid time as a result of falling sales, distribution issues, and US tariffs, the Dr Martens (LSE:DOCS) share price has been on the back foot since its IPO.
Admittedly, the stock’s not cheap based on its current financial performance. But if it can achieve the March 2028 (FY28) forecast earnings per share of 6.1p, it’s a different story. The investment case therefore rests on whether this is achievable. I think it is.
Challenges remain. There are many cheaper alternatives out there. And it’s hard to remain relevant in the fashion industry.
However, the group’s turnaround strategy of selling more directly to customers and entering into partnerships in new markets, show signs of working. Its half-year FY26 results revealed a 33% increase in shoe volumes compared to a year earlier.
I reckon the brand retains its iconic status. And despite its woes, it’s been reducing its debt and stock levels. More will be known when the group releases its next trading update on 27 January. But I think it’s one for patient long-term investors to consider.
Lots to choose from
In my opinion, these are just two interesting UK shares. And as the table below shows, analysts appear optimistic about the prospects for the majority of stocks on the FTSE 100 and FTSE 350, with Buy recommendations of 61% and 63%, respectively.
I believe that the stock market will crash or, at the very least, experience a correction soon.
This isn’t me being gloomy. It’s an opinion based on the fact that there have been plenty in history. But the key is not to panic and keep seeking out those bargains. Taking a long-term view is essential when looking to build wealth.
